Somerset Therapeutics, LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
May 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 11, 2027The maintenance fee for Buffer-free, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof (US 11,696,910) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 2 fees due Apr 17 to 24, 2027 · next Apr 17
- 1 fee due Jun 26, 2027The maintenance fee for Methods of efficiently reducing intraocular pressure (US 11,850,249) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 3 fees due Jul 2 to 30, 2027 · next Jul 2
- 1 fee due Oct 30, 2027The maintenance fee for Low pH pilocarpine and brimonidine compound formulations and related methods (US 11,969,410) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 22, 2026
- Aug 25 US 12,714,689 Ready-To-Use Ascorbic Acid Compound Compositions
- 1 term has ended since Aug 22, 2026
- Sep 6 US 11,433,084 Preparation of Microparticulate Methylprednisolone Acetate Suspension · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,707,174 | Aqueous ophthalmic solution of olopatadine In force (reinstated) · USPTO record | In force (reinstated) | USPTO record | |
| US 12,023,315 | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis In force · USPTO record | In force | USPTO record | |
| US 11,400,100 | Effective benzalkonium chloride-free bimatoprost ophthalmic compositions In force · USPTO record | In force | USPTO record | |
| US 11,564,931 | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties In force · USPTO record | In force | USPTO record | |
| US 11,786,538 | Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties In force · USPTO record | In force | USPTO record | |
| US 11,517,522 | Aprepitant ready-to-use injection emulsion compositions In force · USPTO record | In force | USPTO record | |
| US 11,298,368 | Efficient tobramycin compound conjugate compositions In force · USPTO record | In force | USPTO record | |
| US 11,395,831 | Combination products of tobramycin compounds and dexameihasone compounds In force · USPTO record | In force | USPTO record | |
| US 11,478,491 | Tobramycin compound-copolymer conjugates and derivative compositions In force · USPTO record | In force | USPTO record | |
| US 11,478,492 | Tobramycin compound conjugate formulations In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 40: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 14 no status recorded